Last reviewed · How we verify

NCT05095857: KETA-BID

The Anaesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury

Recruiting now Phase 4 Last updated 26 June 2024
What this trial tests

Phase 4 trial testing S-ketamine in Subarachnoid Hemorrhage, Aneurysmal in 400 participants. Currently enrolling.

Timeline
15 September 2023
Primary endpoint
15 September 2028
15 September 2028

Quick facts

Lead sponsorRigshospitalet, Denmark
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment400
Start date15 September 2023
Primary completion15 September 2028
Estimated completion15 September 2028
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

18 and older, any sex, with Subarachnoid Hemorrhage, Aneurysmal or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cortical spreading depolarisations are pathological depolarisation waves that occur frequently after severe acute brain injury and has been associated with poor outcome. S-ketamine has been shown to inhibit cortical spreading depolarisations. The aim of the present study is to examine the efficacy and safety of using S-ketamine for treatment of patients with severe acute brain injury, as well as the feasibility of the trial design.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of S-ketamine

Trials testing the same drug.

Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05095857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing